Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNJ013
MIFTS: 65

Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Conjunctivitis

About this section

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 74 29 54 3 43 15 62 17 71 32
Madras Eye 12

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:6195
ICD9CM 34 372.30
MeSH 43 D003231
NCIt 49 C34504
SNOMED-CT 67 9826008
UMLS 71 C0009763
Sources

Summaries for Conjunctivitis

About this section
PubMed Health : 62 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and vernal conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 74 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1533)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 34.4 RNASE3 IL6 IL4 CXCL8 CCL11
2 vernal conjunctivitis 34.3 RNASE3 IL4 IGHE IFNG
3 papillary conjunctivitis 34.2 IL6 IL4 CXCL8 CCL11
4 chronic conjunctivitis 32.8 TNF RNASE3 IL6 IL5 IL4 IL33
5 blepharitis 32.8 TNF IL6 IL4
6 familial cold autoinflammatory syndrome 32.6 NLRP3 NLRP12 NLRC4
7 stevens-johnson syndrome/toxic epidermal necrolysis 32.5 IL5 IL2 IL13 IFNG
8 avian influenza 32.5 TNF IL6 CXCL8
9 pollen allergy 32.4 RNASE3 IL5 IL13 IGHE ICAM1
10 kawasaki disease 32.4 TNF IL6 IL4 IL2 IL10
11 graves' disease 32.4 IL4 IL13 IFNG ICAM1
12 reactive arthritis 32.4 TNF IL6 IL10 IFNG CXCL8
13 measles 32.3 TNF TLR3 IL6 IL2 IFNG CXCL8
14 allergic conjunctivitis 32.3 TNF TLR3 RNASE3 IL5 IL4 IL33
15 muckle-wells syndrome 32.1 TNF NLRP3 NLRP12 NLRC4 CXCL8
16 trichinosis 32.1 IL5 IL4 IL13 IL10
17 periodic fever, familial, autosomal dominant 32.0 TNF NLRP3 NLRP12 IL6 CXCL8
18 rubella 31.7 TNF TLR3 IL6 IL5 IL4 IL2
19 trachoma 31.5 TNF IL6 IL4 IL10
20 allergic rhinitis 31.4 RNASE3 IL5 IL4 IL13 IL10 IGHE
21 eye disease 31.3 TNF IL6 IL5 IL4 IL2 IL13
22 haemophilus influenzae 31.3 TNF CXCL8
23 hashimoto thyroiditis 31.3 TNF IL6 IL5 IL4 IL2 IL10
24 keratitis, hereditary 31.2 TNF NLRP3 IL6
25 urethritis 31.2 TNF IL6 CXCL8
26 chlamydia 31.1 TNF IL6 IL5 IL4 IL10 IFNG
27 vernal keratoconjunctivitis 31.0 RNASE3 IL5 IL4 IL13 IGHE CCL11
28 keratoconjunctivitis 30.9 TNF RNASE3 IL6 IL5 IL4 IL2
29 dacryoadenitis 30.9 IL4 IL13 IL10
30 cytokine deficiency 30.8 IL5 IL13
31 iridocyclitis 30.8 TNF IL6 IL10
32 atopic keratoconjunctivitis 30.8 RNASE3 IL5 IL4 IL2 IGHE IFNG
33 keratopathy 30.7 TNF IL4 ICAM1 CXCL8
34 scleritis 30.7 TNF IL5 IL4 IFNG
35 endophthalmitis 30.7 TNF PLG IL6 ICAM1 CXCL8
36 chlamydia pneumonia 30.6 TNF IL6 IL10 CXCL8
37 vasculitis 30.6 TNF IL6 IL10 ICAM1
38 cholera 30.6 TNF IL6 IL4 CXCL8
39 pharyngitis 30.6 TNF NLRP3 IL6 CXCL8
40 poliomyelitis 30.6 TNF IL4 IL10 IFNG ICAM1
41 pemphigus 30.6 TNF IL6 IL4 IL10
42 hypopyon 30.6 TNF IL6 IL10
43 graft-versus-host disease 30.5 TNF IL6 IL2 IL10 IFNG
44 retinal detachment 30.5 TNF IL6 IL10 IFNG CXCL8
45 spondylitis 30.4 TNF IL6 IL10 IFNG
46 exanthem 30.4 TNF NLRP3 IL6 IL2 IL10 IFNG
47 mycobacterium abscessus 30.4 TNF NLRP3 CXCL8
48 central nervous system lymphoma 30.4 TNF IL6 IL2 IL10
49 rosacea 30.4 TNF IL6 IL33 CXCL8
50 periodontitis 30.4 TNF IL6 IL4 IL10 IFNG ICAM1

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis
Sources

Symptoms & Phenotypes for Conjunctivitis

About this section

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 CCL11 HRH1 ICAM1 IFNG IL10 IL13
2 immune system MP:0005387 10.36 CCL11 HRH1 ICAM1 IFNG IL10 IL13
3 cellular MP:0005384 10.35 ICAM1 IFNG IL10 IL13 IL2 IL33
4 digestive/alimentary MP:0005381 10.34 ICAM1 IFNG IL10 IL13 IL2 IL33
5 homeostasis/metabolism MP:0005376 10.33 HRH1 ICAM1 IFNG IL10 IL13 IL2
6 growth/size/body region MP:0005378 10.31 HRH1 ICAM1 IFNG IL10 IL13 IL2
7 endocrine/exocrine gland MP:0005379 10.25 ICAM1 IFNG IL10 IL13 IL2 IL33
8 integument MP:0010771 10.1 ICAM1 IFNG IL10 IL13 IL33 IL4
9 liver/biliary system MP:0005370 10.07 HRH1 IFNG IL10 IL2 IL4 IL5
10 neoplasm MP:0002006 10.02 ICAM1 IFNG IL10 IL2 IL5 IL6
11 nervous system MP:0003631 10 ICAM1 IFNG IL10 IL13 IL33 IL4
12 reproductive system MP:0005389 9.73 IFNG IL10 IL13 IL2 IL33 IL4
13 no phenotypic analysis MP:0003012 9.7 IFNG IL10 IL13 IL2 IL33 IL4
14 respiratory system MP:0005388 9.4 CCL11 IFNG IL10 IL13 IL2 IL33
Sources

Drugs & Therapeutics for Conjunctivitis

About this section

PubMed Health treatment related to Conjunctivitis: 62

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection , even though conjunctivitis is more commonly caused by viruses . But antibiotics are only effective against bacteria , and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy , it can be treated with allergy medicine such as antihistamines .

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
3
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
4
Alcaftadine Approved Phase 4 147084-10-4 19371515
5
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
13
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
14
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
15
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
16
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
17
Dipivefrin Approved Phase 4 52365-63-6 3105
18
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
19
Montelukast Approved Phase 4 158966-92-8 5281040
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Ranibizumab Approved Phase 4 347396-82-1 459903
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
26
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
27
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
28
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
29
Tranilast Investigational Phase 4 53902-12-8 93543
30 Ketorolac Tromethamine Phase 4
31 Keratolytic Agents Phase 4
32 Respiratory System Agents Phase 4
33 Dermatologic Agents Phase 4
34 Immunosuppressive Agents Phase 4
35 Calcineurin Inhibitors Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Platelet Aggregation Inhibitors Phase 4
39 Calcium, Dietary Phase 4
40 calcium channel blockers Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Bronchodilator Agents Phase 4
43 Dextrans Phase 4
44 Anticoagulants Phase 4
45 Polymyxins Phase 4
46 Cyclosporins Phase 4
47 Cholinergic Agents Phase 4
48 Cholinergic Antagonists Phase 4
49 Leukotriene Antagonists Phase 4
50 Antifungal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 431)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaftâ„¢) Unknown status NCT01808768 Phase 4 Alcaftadine
4 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
5 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
6 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
7 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
8 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
9 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
10 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
11 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
12 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
13 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
14 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
15 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
16 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
17 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
18 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
19 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
20 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
21 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
22 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
23 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
24 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
25 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
26 A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. Completed NCT00581542 Phase 4 moxifloxacin;polytrim
27 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
28 A Study to Evaluate the Efficacy of Lastacaft® Compared to Patadayâ„¢ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
29 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
30 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
31 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
32 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
33 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
34 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
35 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
36 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
37 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
38 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
39 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
40 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
41 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
42 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
43 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
44 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
45 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
46 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
47 The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
48 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
49 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
50 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cromolyn
Cromolyn Sodium
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate

Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

About this section

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 29
Sources

Anatomical Context for Conjunctivitis

About this section

MalaCards organs/tissues related to Conjunctivitis:

40
Eye, Testes, Skin, T Cells, Colon, Breast, Kidney
Sources

Publications for Conjunctivitis

About this section

Articles related to Conjunctivitis:

(show top 50) (show all 11036)
# Title Authors PMID Year
1
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 54 61
20361659 2009
2
Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. 54 61
18379431 2008
3
IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). 54 61
18327049 2008
4
[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. 54 61
17277873 2006
5
[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. 61 54
16491868 2006
6
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 54 61
15245511 2004
7
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. 61 54
11443543 2001
8
Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. 61 54
11148813 2000
9
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 61 54
10756233 2000
10
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. 61 54
9856836 1998
11
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. 54 61
9759406 1998
12
Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. 61 54
9602632 1998
13
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. 54 61
8648032 1996
14
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. 61 54
8612470 1995
15
A review on Zika virus outbreak, epidemiology, transmission and infection dynamics. 61
32158705 2020
16
Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control - a comprehensive review. 61
32315579 2020
17
Corneal melt in conjunctival intraepithelial neoplasia. 61
32426552 2020
18
Complicated case of Mycobacterium abscessus conjunctivitis in Sjögren's syndrome. 61
32548334 2020
19
Ectoparasitism during an avian disease outbreak: An experiment with Mycoplasma-infected house finches and ticks. 61
32426219 2020
20
Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. 61
32450165 2020
21
Case Manifestations and Public Health Response for Outbreak of Meningococcal W Disease, Central Australia, 2017. 61
32568047 2020
22
The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: ~9 years' follow-up on tumor control. 61
32311432 2020
23
Poly(2-hydroxyethyl methacrylate)/β-cyclodextrin-hyaluronan contact lens with tear protein adsorption resistance and sustained drug delivery for ophthalmic diseases. 61
32339710 2020
24
A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. 61
32333104 2020
25
The evidence of SARS-CoV-2 infection on ocular surface. 61
32289466 2020
26
Atypical Manifestations of Cat-Scratch Disease, United States, 2005-2014. 61
32568056 2020
27
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. 61
32438340 2020
28
A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. 61
32222367 2020
29
Clinical clues predictive of Stevens-Johnson syndrome as the cause of chronic cicatrising conjunctivitis. 61
31630093 2020
30
Asthma phenotypes and associated comorbidities in a large cohort of adolescents in Israel. 61
31017024 2020
31
Giant papillary conjunctivitis: A review. 61
32339665 2020
32
Diesel particulate matter2.5 promotes epithelial-mesenchymal transition of human retinal pigment epithelial cells via generation of reactive oxygen species. 61
32155554 2020
33
Formulation of Chitosan Polymeric Vesicles of Ciprofloxacin for Ocular Delivery: Box-Behnken Optimization, In Vitro Characterization, HET-CAM Irritation, and Antimicrobial Assessment. 61
32504176 2020
34
Epidemiology and Clinical Symptoms Related to Seasonal Coronavirus Identified in Patients with Acute Respiratory Infections Consulting in Primary Care over Six Influenza Seasons (2014-2020) in France. 61
32532138 2020
35
Ocular Anterior Segment Pathology in the Emergency Department: A 5-Year Study. 61
32568931 2020
36
Body condition and poxvirus infection predict circulating glucose levels in a colorful songbird that inhabits urban and rural environments. 61
32515908 2020
37
Pre-operative conjunctival flora in patients with local and/or systemic risk factors for post cataract surgery infection in Northern Italy. 61
32552180 2020
38
Corneal perforation associated with isolated ocular lichen planus: a case report. 61
32493062 2020
39
Hyperacute conjunctivitis in young patient. 61
32534742 2020
40
Evaluation of Conjunctival Swab PCR Results in Patients with SARS-CoV-2 Infection. 61
32569495 2020
41
Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. 61
32100876 2020
42
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies. 61
32568435 2020
43
Sympathetic Nerves Positively Regulate Eosinophil-Driven Allergic Conjunctivitis via α1-Adrenergic Receptor Signaling. 61
32194050 2020
44
The burden of acute conjunctivitis attributable to ambient particulate matter pollution in Singapore and its exacerbation during South-East Asian haze episodes. 61
32562998 2020
45
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. 61
32501774 2020
46
The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. 61
32558665 2020
47
Ocular manifestations of coronavirus disease 2019. 61
32504100 2020
48
Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. 61
32265202 2020
49
Ocular Signs of COVID-19 Suggested by Internet Search Term Patterns Worldwide. 61
32562704 2020
50
COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations. 61
32543262 2020
Sources

Variations for Conjunctivitis

About this section
Sources

Expression for Conjunctivitis

About this section
Search GEO for disease gene expression data for Conjunctivitis.
Sources

Pathways for Conjunctivitis

About this section

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.1 TNF TLR3 RNASE3 NLRP3 NLRC4 IL6
2
ERK Signaling 63
Show member pathways
 13.88 TNF IL6 IL5 IL4 IL2 IL13
3
PEDF Induced Signaling 63
Show member pathways
 13.78 TNF IL6 IL5 IL4 IL33 IL2
4
TGF-Beta Pathway 63
Show member pathways
 13.66 TNF IL6 IL5 IL4 IL2 IL13
5
Akt Signaling 63
Show member pathways
 13.53 TNF TLR3 IL6 IL5 IL4 IL2
6
PAK Pathway 63
Show member pathways
 13.42 TNF IL6 IL5 IL4 IL2 IL13
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.42 TNF IL6 IL5 IL4 IL33 IL2
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.16 TNF TLR3 IL6 IL2 IL10 IFNG
9
Pathways in cancer 36
12.97 IL6 IL5 IL4 IL2 IL13 IFNG
10
Measles 36
Show member pathways
 12.92 TNF TLR3 PLG NLRP3 IL6 IL33
11
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.87 TNF TLR3 NLRP3 NLRP12 NLRC4 IL6
12
Allograft rejection 1 36
Show member pathways
 12.78 TNF RNASE3 IL6 IL5 IL4 IL2
13
Immune response NFAT in immune response 22
Show member pathways
 12.75 TNF IL4 IL2 IL10 IGHE IFNG
14
T cell receptor signaling pathway 36
Show member pathways
 12.75 TNF IL6 IL5 IL4 IL2 IL10
15
Th17 cell differentiation 36
Show member pathways
 12.74 TNF IL6 IL5 IL4 IL2 IL13
16
Immune response IL-23 signaling pathway 22
Show member pathways
 12.72 TNF PLG IL6 IL2 IL10 IFNG
17
NF-kappaB Signaling 4
12.7 TNF TLR3 IL4 IL2 IL10 IFNG
18
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.67 TNF IL5 IL4 IL13 IGHE
19
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.61 TNF IL4 IL2 IFNG ICAM1
20
JAK-STAT signaling pathway 36
Show member pathways
 12.6 IL6 IL5 IL4 IL2 IL13 IL10
21
Folate Metabolism 1
Show member pathways
 12.5 TNF PLG IL6 IL4 IL2 IFNG
22
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.48 TNF IL6 IL2 IL10 CXCL8 CCL11
23
IL-17 Family Signaling Pathways 64
Show member pathways
 12.48 TNF IL6 IL5 IL4 IL13 IFNG
24
Shigellosis 36
12.45 TNF NLRP3 NLRC4 CXCL8
25
Development IGF-1 receptor signaling 22
Show member pathways
 12.44 IL4 IGHE HRH1 CCL11
26
Toll Comparative Pathway 63
Show member pathways
 12.43 TNF TLR3 IL6 IFNG CXCL8
27
Salmonella infection (KEGG) 36
12.43 TNF NLRP3 NLRC4 IL6 CXCL8
28
Human T-cell leukemia virus 1 infection 36
12.4 TNF IL6 IL2 ICAM1
29
NOD-like receptor signaling pathway 36
12.39 TNF NLRP3 NLRP12 NLRC4 IL6 CXCL8
30
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.39 TNF IL6 IL5 IL4 IL2 IL13
31
C-type lectin receptor signaling pathway 36
Show member pathways
 12.35 TNF NLRP3 IL6 IL2 IL10
32
Pathogenic Escherichia coli infection 36
12.34 TNF NLRP3 IL6 CXCL8
33
Necroptosis 36
Show member pathways
 12.34 TNF TLR3 NLRP3 IL33 IFNG
34
Bacterial infections in CF airways 22
Show member pathways
 12.34 TNF IL6 IL4 IFNG CXCL8 CCL11
35
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.33 TNF TLR3 IL6 CXCL8
36
Toxoplasmosis 36
Show member pathways
 12.33 TNF IL4 IL10 IFNG
37
Tuberculosis 36
12.31 TNF IL6 IL10 IFNG
38
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.31 TNF IL6 IL13 IL10 CXCL8
39
Colorectal Cancer Metastasis 63
12.27 TNF TLR3 IL6 IFNG
40
Yersinia infection 36
12.19 TNF NLRP3 IL6 IL2 IL10 CXCL8
41
Spinal Cord Injury 1
12.19 TNF IL6 IL4 IL2 IFNG ICAM1
42
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.17 TNF IL6 IL5 IL4 IL2 IL10
43
MAPK Pathway 70
Show member pathways
 12.13 TLR3 IL5 IL2 IL13
44
IL27-mediated signaling events 1
Show member pathways
 12.12 TNF TLR3 IL6 IL2 IL10 IFNG
45
Amoebiasis 36
12.09 TNF IL6 IL10 IFNG CXCL8
46
Rheumatoid arthritis 36
12.04 TNF IL6 IFNG ICAM1 CXCL8
47
AGE-RAGE signaling pathway in diabetic complications 36
12.03 TNF IL6 ICAM1 CXCL8
48
Hematopoietic cell lineage 36
12.02 TNF IL6 IL5 IL4
49
Th17 Differentiation 64
Show member pathways
 11.98 TLR3 IL6 IL4 IFNG
50
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.95 TNF IL5 IL4 IL2 IFNG CXCL8
Sources

GO Terms for Conjunctivitis

About this section

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF RNASE3 PLG NLRP3 IL6 IL5
2 extracellular space GO:0005615 9.5 TNF TLR3 RNASE3 PLG IL6 IL5

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 TLR3 NLRP3 NLRP12 IL6 IL5 IL4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 TNF TLR3 NLRP3 IL6 IL4 IL33
3 positive regulation of gene expression GO:0010628 10.12 TNF TLR3 IL6 IL4 IL33 IL13
4 defense response to bacterium GO:0042742 10.02 TNF TLR3 RNASE3 NLRC4 IL10 IGHE
5 defense response to virus GO:0051607 10.01 TLR3 NLRP3 IL6 IL33 IFNG
6 defense response GO:0006952 9.99 TNF TLR3 NLRP3 CXCL8
7 cellular response to lipopolysaccharide GO:0071222 9.97 TNF NLRP3 IL6 IL10 ICAM1 CXCL8
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL5 IL10
9 defense response to Gram-positive bacterium GO:0050830 9.96 TNF RNASE3 NLRP3 IL6
10 response to virus GO:0009615 9.95 TNF TLR3 IFNG CCL11
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF TLR3 NLRP3 NLRC4 IL6 ICAM1
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.93 TNF NLRP3 NLRP12 NLRC4
13 negative regulation of inflammatory response GO:0050728 9.93 NLRP3 NLRP12 IL4 IL2 IL13 IL10
14 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR3 NLRP12
16 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL4 IL2
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF IL6 IL13
18 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR3 IL6 IL33
19 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF IFNG ICAM1
21 extrinsic apoptotic signaling pathway GO:0097191 9.86 TNF TLR3 IL33 IFNG
22 positive regulation of cytokine production GO:0001819 9.85 TNF TLR3 IL33
23 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR3 NLRP12 IL33 IL2 IFNG
24 inflammatory response GO:0006954 9.85 TNF TLR3 NLRP3 NLRC4 IL6 IL5
25 positive regulation of cytokine secretion GO:0050715 9.84 TNF IL10 IFNG
26 positive regulation of B cell proliferation GO:0030890 9.84 IL5 IL4 IL2 IL13
27 negative regulation of endothelial cell apoptotic process GO:2000352 9.83 IL4 IL13 IL10 ICAM1
28 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 CCL11
29 positive regulation of JAK-STAT cascade GO:0046427 9.81 TNF IL6 IL5 IL10
30 positive regulation of chemokine production GO:0032722 9.8 TNF TLR3 IL6
31 positive regulation of macrophage activation GO:0043032 9.79 IL33 IL13 IL10
32 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.78 TNF IL6 ICAM1
33 positive regulation of neuroinflammatory response GO:0150078 9.77 TNF IL6 IL33
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.76 IL4 IL10 IFNG
35 positive regulation of interleukin-10 secretion GO:2001181 9.74 IL4 IL13
36 positive regulation of mast cell degranulation GO:0043306 9.74 IL4 IL13
37 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.74 IL4 IL10
38 response to molecule of bacterial origin GO:0002237 9.74 IL10 CXCL8
39 positive regulation of interleukin-13 production GO:0032736 9.74 NLRP3 IL4 IL33
40 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
41 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL4 IL2
42 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
43 negative regulation of T-helper 17 cell differentiation GO:2000320 9.73 IL4 IL2
44 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.73 TNF IFNG
45 positive regulation of chemokine biosynthetic process GO:0045080 9.73 TNF TLR3 IL4 IFNG
46 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL6 IL4 IL2 IL13 IFNG
47 necroptotic signaling pathway GO:0097527 9.72 TNF TLR3
48 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
49 positive regulation of interleukin-5 production GO:0032754 9.72 NLRP3 IL33
50 negative regulation of acute inflammatory response GO:0002674 9.72 NLRP3 IL4

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF IL6 IL5 IL4 IL33 IL2
2 growth factor activity GO:0008083 9.35 IL6 IL5 IL4 IL2 IL10
Sources

Sources for Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....